Geographic Variations in the Use of Medical and Surgical Therapies for Benign Prostatic Hyperplasia
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (3) , 1023-1027
- https://doi.org/10.1016/s0022-5347(05)00409-x
Abstract
Patients with BPH have several treatment options. Little is known about geographic variations in surgical rates for BPH and the market relationships to medical therapy, health resources and sociodemographic factors. We conducted a cross-sectional study using administrative data from 5 states in 2000. Rates of surgical and medical therapy were calculated per 100,000 men 55 years old or older. Main outcome measures were county level weighted coefficient of variation and systematic component of variation in therapy rates, as well as surgery rates as a function of medication dispensing rates, health care resources and sociodemographic characteristics. North Carolina had the lowest surgery rates (26.3 minimally invasive procedures and 332.1 invasive surgeries per 100,000) and finasteride dispensing rates (503.5 per 100,000). Overall rates of medical therapy were 5 times higher than surgery rates. Geographic variations in surgical and medical therapy rates were significant for each state, and North Carolina had the greatest variation. An increase of 11.6 per 100,000 (95% CI, 6.5-55.8) in annual county level finasteride dispensing would be associated with a decrease in the surgery rate of 1 per 100,000, controlling for other variables. There is significant systematic variation in rates of surgical and medical therapy for BPH at county and state levels. The relationship between finasteride and surgery in randomized clinical trials is generalizable to the marketplace. Finasteride rates are inversely related to surgery rates, and tamsulosin rates are positively associated with surgery rates. Surgery rates are not significantly associated with urologists per capita.Keywords
This publication has 13 references indexed in Scilit:
- Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002JAMA, 2004
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003
- Tamsulosin: an overviewWorld Journal of Urology, 2002
- Terazosin, doxazosin, and prazosin: current clinical experienceUrology, 2001
- Threats to Applicability of Randomised Trials: Exclusions and Selective ParticipationJournal of Health Services Research & Policy, 1999
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- The national cancer data base report on race, age, and region variations in prostate cancer treatmentCancer, 1997
- A Nationwide Survey of Practicing Urologists: Current Management of Benign Prostatic Hyperplasia and Clinically Localized Prostate CancerJournal of Urology, 1997
- Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based StudyJNCI Journal of the National Cancer Institute, 1996
- Small-Area Variations in the Use of Common Surgical Procedures: An International Comparison of New England, England, and NorwayNew England Journal of Medicine, 1982